Abstract
Imatinib mesylate is a tyrosine kinase inhibitor with preferential activity toward the bcr-abl fusion protein of chronic myelogenous leukemia (CML).1 Imatinib mesylate is also active against a limited number of other tyrosine kinases, including c-kit, PDGFR and PDGFR.2 Significant clinical activity has been demonstrated in diseases in which these tyrosine kinases play a major role, including a variety of myeloproliferative disorders such as the hypereosinophilic syndromes.3 Currently, we report on a patient with an atypical myeloproliferative disorder and a novel balanced translocation who had a dramatic clinical response to imatinib mesylate. The specific target in this patient is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
